CR20200375A - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents

Anticuerpos agonistas contra pd-1 y usos de estos

Info

Publication number
CR20200375A
CR20200375A CR20200375A CR20200375A CR20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A
Authority
CR
Costa Rica
Prior art keywords
agonist antibodies
antibodies against
tissues
human
rheumatoid arthritis
Prior art date
Application number
CR20200375A
Other languages
English (en)
Inventor
Pia Pauliina Yachi
Kristin Paige Newburn
Stephanie Marie Truhlar
Qing Chai
Yiqing Feng
Petra Verdino
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20200375A publication Critical patent/CR20200375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se refiere a anticuerpos agonistas anti-PD-1 humana y sus usos para tratar trastornos autoinmunitarios, tales como la artritis reumatoide, o para disminuir el rechazo de células y/o tejidos trasplantados.</p>
CR20200375A 2018-03-02 2019-02-22 Anticuerpos agonistas contra pd-1 y usos de estos CR20200375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
PCT/US2019/019076 WO2019168745A1 (en) 2018-03-02 2019-02-22 Pd-1 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20200375A true CR20200375A (es) 2020-09-25

Family

ID=65686121

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200375A CR20200375A (es) 2018-03-02 2019-02-22 Anticuerpos agonistas contra pd-1 y usos de estos

Country Status (26)

Country Link
US (1) US10493148B2 (es)
EP (1) EP3759139A1 (es)
JP (3) JP7071521B2 (es)
KR (2) KR102536014B1 (es)
CN (4) CN118903407A (es)
AR (1) AR114127A1 (es)
AU (2) AU2019228474B2 (es)
BR (1) BR112020015983A2 (es)
CA (1) CA3092064C (es)
CL (1) CL2020002180A1 (es)
CO (1) CO2020010188A2 (es)
CR (1) CR20200375A (es)
DO (1) DOP2020000153A (es)
EA (1) EA202091809A1 (es)
EC (1) ECSP20053544A (es)
IL (1) IL276340A (es)
JO (1) JOP20200210A1 (es)
MA (1) MA52414A (es)
MX (1) MX2020009124A (es)
PE (1) PE20210045A1 (es)
PH (1) PH12020551463A1 (es)
SA (1) SA520420082B1 (es)
SG (1) SG11202008437WA (es)
TW (1) TWI708787B (es)
WO (1) WO2019168745A1 (es)
ZA (1) ZA202004601B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362074B1 (en) * 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018282094B2 (en) 2017-06-05 2024-06-27 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TWI829677B (zh) * 2018-03-20 2024-01-21 大陸商上海藥明生物技術有限公司 新型抗pd-1抗體
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
AU2020274027A1 (en) 2019-05-10 2021-11-11 The Regents Of The University Of California Modified pluripotent cells
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
US20230212293A1 (en) * 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
JP7754455B2 (ja) * 2020-05-25 2025-10-15 公益財団法人神戸医療産業都市推進機構 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
AU2022272835A1 (en) 2021-05-13 2023-11-02 Foundation For Biomedical Research And Innovation At Kobe Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
MX2024006098A (es) 2021-11-19 2024-05-30 Mirobio Ltd Anticuerpos pd-1 dise?ados por ingenieria y usos de estos.
WO2023147470A2 (en) * 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
EP4507727A1 (en) * 2022-04-13 2025-02-19 The Regents of the University of California Immune cell inhibition by immune checkpoint engagers
JP2025525438A (ja) * 2022-07-06 2025-08-05 サンタ アナ バイオ インコーポレイテッド 自己免疫性疾患、アレルギー性疾患、及び炎症性疾患を治療するための方法及び組成物
CA3265104A1 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company PD-1 AGONIST ANTIBODIES AND METHODS OF TREATMENT OF AUTOIMMUNE DISEASES WITH A PD-1 AGONIST ANTIBODY
EP4580674A2 (en) * 2022-08-30 2025-07-09 Flagship Pioneering Innovations VI, LLC Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
WO2024196694A2 (en) * 2023-03-17 2024-09-26 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating inflammatory or autoimmune skin diseases with a pd-1 agonist antibody
WO2025042732A1 (en) * 2023-08-18 2025-02-27 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
CN120424213A (zh) * 2024-02-02 2025-08-05 英诺湖医药(杭州)有限公司 特异性结合pd-1的单克隆抗体及其医药用途
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP3939613A1 (en) * 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
US10047137B2 (en) 2013-04-05 2018-08-14 Versitech Limited Antibodies against novel PD1 isoforms and uses thereof
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982053B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
EP3313883B1 (en) 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
HK1251158A1 (zh) * 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
SG10201912943RA (en) 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
IL257858B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Anti-pd1 antibodies and methods of use
US10858432B2 (en) 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
AU2018282094B2 (en) 2017-06-05 2024-06-27 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
EA202091809A1 (ru) 2020-11-23
AU2019228474B2 (en) 2023-04-13
AU2019228474A1 (en) 2020-08-20
JP2021516235A (ja) 2021-07-01
AR114127A1 (es) 2020-07-22
US20190270818A1 (en) 2019-09-05
CN118903407A (zh) 2024-11-08
DOP2020000153A (es) 2020-09-15
ZA202004601B (en) 2022-03-30
JP2022088411A (ja) 2022-06-14
CN111886253A (zh) 2020-11-03
JP2023093549A (ja) 2023-07-04
CL2020002180A1 (es) 2021-01-04
KR102536014B1 (ko) 2023-05-24
ECSP20053544A (es) 2020-10-30
PE20210045A1 (es) 2021-01-08
IL276340A (en) 2020-09-30
CA3092064A1 (en) 2019-09-06
CN118846042A (zh) 2024-10-29
WO2019168745A1 (en) 2019-09-06
TWI708787B (zh) 2020-11-01
NZ766604A (en) 2024-10-25
JP7071521B2 (ja) 2022-05-19
JOP20200210A1 (ar) 2020-08-30
CN118806891A (zh) 2024-10-22
US10493148B2 (en) 2019-12-03
PH12020551463A1 (en) 2021-09-01
MX2020009124A (es) 2020-09-28
CA3092064C (en) 2024-01-02
TW201942133A (zh) 2019-11-01
JP7259107B2 (ja) 2023-04-17
CO2020010188A2 (es) 2020-08-31
CN111886253B (zh) 2024-08-27
AU2023204569A1 (en) 2023-10-26
BR112020015983A2 (pt) 2020-12-15
MA52414A (fr) 2021-01-06
SG11202008437WA (en) 2020-09-29
KR20230079458A (ko) 2023-06-07
KR20200115614A (ko) 2020-10-07
EP3759139A1 (en) 2021-01-06
SA520420082B1 (ar) 2022-11-11

Similar Documents

Publication Publication Date Title
CR20200375A (es) Anticuerpos agonistas contra pd-1 y usos de estos
UY38182A (es) Receptores quiméricos de dll3 y métodos para su uso
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d&#39;utilisation
MX395639B (es) Composiciones y métodos para el agotamiento de células cd137+.
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
MX392748B (es) Anticuerpos anti-cd40 y sus usos.
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
EA201390725A1 (ru) Молчащие fc-варианты анти-cd40 антител
EA201391755A1 (ru) Анти-kir антитела для лечения воспалительных заболеваний
EA201791629A1 (ru) 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
PH12021550096A1 (en) Compositions of fcrn antibodies and methods of use thereof
CL2022002429A1 (es) Anticuerpos anti-interleucina-33 y usos de estos.
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
EA201892005A1 (ru) Композиции и способы для лечения ревматоидного артрита
MX2022015801A (es) Sistemas de expresion de baculovirus.
ZA202006216B (en) Antibodies targeting glycoprotein vi
EA201990128A1 (ru) Культуры клеточных линий из растений, принадлежащих к роду harpagophytum
AU2017248848A1 (en) Enhanced gene delivery methods
GEAP202415617A (en) Antibody variants